201609-37-2

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 4-methoxy-4-phenyl-, 1,1-dimethylethyl ester
• Synonyms: 1-t-Butoxycarbonyl-4-methoxy-4-phenylpiperidine;4-methoxy-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester
• CAS NO: 201609-37-2
• Molecular Formula: C17H25NO3
• Molecular Weight: 291.39
• Mol File: 201609-37-2.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 4-methoxy-4-phenyl-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 4-methoxy-4-phenyl-, 1,1-dimethylethyl ester(201609-37-2)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 4-methoxy-4-phenyl-, 1,1-dimethylethyl ester(201609-37-2)

Safety Data

• Hazardous Substances Data: 201609-37-2(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 40807-61-2 4-hydroxy-4-phenylpiperidin 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 591-51-5 phenyllithium 
• 74-88-4 methyl iodide 
• 172734-33-7 4-hydroxy-4-phenylpiperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 201609-38-3 4‐methoxy‐4‐phenylpiperidine 
• 201608-95-9 2a-[4-(4-methoxy-4-phenyl-piperidyl)butyl]-2a,3,4,5-tetrahydrobenz[cd]indole-2(1H)-one 
• 83949-38-6 4-methoxy-4-phenylpiperidine hydrochloride 

Relevant articles and documents

Propafenone analogue with additional H-bond acceptor group shows increased inhibitory activity on P-glycoprotein

P-glycoprotein (P-gp) is an ATP-dependent efflux pump that has a marked impact on the absorption, distribution, and excretion of therapeutic drugs. As P-gp inhibition can result in drug–drug interactions and altered drug bioavailability, identifying molec

(4-PHENYL-PIPERIDIN-1-YL)-[5-1H-PYRAZOL-4YL)-THIOPHEN-3-YL]-METHANONE COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)- [5-(1 H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11 β-hydroxysteroid dehydrogenase type 1 (11 β-HSD1 ). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 1 1 β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11 β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS

Compounds of formula (I) are useful in the treatment of vanilloid-receptor-meditated diseases, such as inflammatory or neuropathic pain and diseases involving sensory nerve function such as asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis.